INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro(TM) for Early Alzheimer’s Disease
November 27, 2023
INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4
July 28, 2021
Related Post
-
-
Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD
November 21, 2023
-
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
November 15, 2023
-
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
November 14, 2023